THE TAPE
NEO · Testing Laboratories · $2.0B

NeoGenomics, Inc.

$15.41▼ −3.81%
Last close
Relative strength
92RS
of 99, against every stock▼ -2 on the month
Cooling off
Unconfirmed
+83.8%
six months against the S&P 500
52-week range
−23.5%
from the high
$7.07$20.15
Setup
squeezeforming
−12.8%
against the pivot at $17.67
No report date on the calendar.
Growth FLATProof PENDING
Quarter to Sep 30, revenue +11% on a year ago
11/16 O 15.75 H 15.78 L 15.36 Vol 1.2M
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

RS92
vs pivot−12.79%
Tightening—
Dry-up—
Up/down vol-0.07
From high24%
forming2 of 7checks
Cooling off
Support and resistance
Support below
None within the last 120 sessions
Resistance above
$15.52
+0.7% · tested 6× · last 7 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 1.6 weeks and fell 13% from its ceiling at its deepest. The pivot is $17.67, and the stock closed 12.8% below it. Its relative strength rating is 92.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against the S&P 500
-4.5%
Three months against the S&P 500
+0.5%
Six months against the S&P 500
+83.8%

Its industry has too few members to make an index of, so it is read against the S&P 500 and can only be turning, caution or unconfirmed.

Peers
Same industry
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 9.7% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$787.8M
+11.4% year on year
Operating margin
-6.3%
gross 44.8%
Net margin
-4.1%
Free cash flow
$-28.6M
-1.4% of market cap
Price to sales
2.53×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 28
Key takeaway
Cash flow is the weak point of the quarter.
Revenue
$209.3M
+3.8% QoQ · +11.4% YoY
Gross margin
46.2%
+0.6 pts QoQ
Net income
−$7.5M
Loss
Free cash flow
−$20.7M
Burning · 7q runway

What the numbers say

  • Revenue +11.4% year over year, +3.8% on the quarter
  • Gross margin 46.2%, +0.6 points on the quarter
  • Weak: Net loss $8M
  • Weak: Burning cash: operating cash flow -$9M, free cash flow -$21M, worse than $12M last quarter · 7 quarters of cash at this burn
  • Weak: Growth externally funded: capex $12M against operating cash flow -$9M
  • Net debt $235M · cash $139M
Revenue by quarter
Free cash flow
Net income
shares +0.1% in a year · net debt $235.4M

What is not obvious

  • Weak: Stock compensation $9M added back against negative operating cash flow
  • Weak: Interest $1M a quarter against an operating loss: the debt is carried by the balance sheet, not operations
Final read
Growth: FLAT · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is operating profit: net loss $8M.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

No tracked fund holds it now at the end of Q3 2026.

Last quarter: 1 sold out.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
GappedTape · 2026-11-03
-5.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-10-30
above 20d & 50d on 1.6x volume at 17.93
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
Reported resultsFiling · 2026-10-29
2.02
No measurable effect: stocks behave like random ones over the next three sessions (2,340 cases over 54 nights).
Earnings comingEvent · 2026-10-27
reports 2026-10-28 amc
No measurable effect: stocks behave like random ones over the next three sessions (2,970 cases over 40 nights).
Earnings date movedEvent · 2026-10-15
2026-10-26 -> 2026-10-28
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).
GappedTape · 2026-10-07
-13.7%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
A director or officer changedFiling · 2026-10-06
2.02,5.02
No measurable effect: stocks behave like random ones over the next three sessions (1,288 cases over 54 nights).
GappedTape · 2026-09-25
+6.5%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
NeoGenomics (NEO) Q3 Earnings and Revenues Beat EstimatesZacks Investment Research · 2026-10-28

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders
Bought on the open market
0
Sold on the open market
3
$440,224 total

Sold: Aunan Greg D, TETRAULT LYNN A..

Not counted above: 13 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-01 Stone Warren · Pres & Chief Operating Officeroption exercise17,562
2026-10-01 Stone Warren · Pres & Chief Operating Officerwithheld for tax6,911
2026-09-01 Olivo Alicia C · EVP, GC & Business Developmentwithheld for tax2,692
2026-08-21 Stone Warren · Pres & Chief Operating Officeroption exercise28,106
2026-08-21 Stone Warren · Pres & Chief Operating Officerwithheld for tax11,060
2026-08-04 Aunan Greg D · Chief Accounting Officersell20,000$321,400
2026-06-15 TETRAULT LYNN A. · Directorsell5,307$58,908
2026-06-09 TETRAULT LYNN A. · Directorsell5,307$59,916

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

The geometry
Level · ceiling$17.67
Wrong below$15.14
Measured target · a squeeze has no height to projectnone
Through to the apex39%
Leaning · and easingdown
Length1.6 weeks

Leaning is where price has been sitting against its own range while the range was quiet. It is not a forecast of which way the range opens up, and this site has no measurement that would support one.

What lines up

2 of 7 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
More up-volume than down-volume
Within 15% of its 52-week high

2 checks are not listed because this stock has too little history to judge them — a 200-day average needs 200 sessions. They are left out of the total rather than counted as failures.

What analysts expect
Strong buy2
Buy6
Hold3
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray
6w · 24%

The most recent of 3 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
NeoGenomics, Inc. (NEO) — The Tape